Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells $5,950,000.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 50,000 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $119.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at approximately $79,321,592. The trade was a 6.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, July 1st, Nello Mainolfi sold 80,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $115.29, for a total transaction of $9,223,200.00.
• On Wednesday, April 29th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $81.18, for a total value of $2,435,400.00.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $119.00 on Friday. Kymera Therapeutics, Inc. has a 1 year low of $36.65 and a 1 year high of $130.05. The company has a market capitalization of $9.79 billion, a P/E ratio of -33.33 and a beta of 1.95. The business has a 50 day moving average of $89.85 and a 200-day moving average of $84.07.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.18. The firm had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.82) earnings per share. Equities analysts anticipate that Kymera Therapeutics, Inc. will post -3.28 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. BTIG Research reiterated a “buy” rating and set a $134.00 price target on shares of Kymera Therapeutics in a report on Thursday, June 25th. Jefferies Financial Group started coverage on shares of Kymera Therapeutics in a report on Monday, March 16th. They set a “buy” rating and a $110.00 price objective on the stock. Canaccord Genuity Group increased their price objective on Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a research note on Friday, June 26th. Brookline Capital Markets restated a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $119.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $121.41.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its stake in Kymera Therapeutics by 27.5% during the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after acquiring an additional 98 shares in the last quarter. US Bancorp DE increased its holdings in Kymera Therapeutics by 9.8% during the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after acquiring an additional 166 shares during the period. Glenmede Trust Co. NA lifted its stake in Kymera Therapeutics by 3.6% in the 1st quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock worth $565,000 after purchasing an additional 235 shares in the last quarter. Cetera Investment Advisers raised its position in shares of Kymera Therapeutics by 7.5% in the first quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock worth $300,000 after buying an additional 252 shares in the last quarter. Finally, Larson Financial Group LLC grew its holdings in shares of Kymera Therapeutics by 36.9% during the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after purchasing an additional 287 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.